{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=SpringWorks+Therapeutics%2C+Inc.%2C+a+healthcare+company+of+Merck+KGaA%2C+Darmstadt%2C+Germany",
    "query": {
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T11:28:56.676Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03785964",
      "title": "Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Desmoid Tumor",
        "Aggressive Fibromatosis"
      ],
      "interventions": [
        {
          "name": "Nirogacestat oral tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2019-04-17",
      "completion_date": "2024-10-17",
      "has_results": true,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-10T11:28:56.676Z",
      "location_count": 34,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 27 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03785964"
    },
    {
      "nct_id": "NCT05041036",
      "title": "Individual Patient Compassionate Use of Nirogacestat",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Desmoid Tumor",
        "NOTCH Gene Mutation Positive Tumors"
      ],
      "interventions": [
        {
          "name": "Nirogacestat (Gamma Secretase Inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-10T11:28:56.676Z",
      "location_count": 1,
      "location_summary": "Billerica, Massachusetts",
      "locations": [
        {
          "city": "Billerica",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05041036"
    },
    {
      "nct_id": "NCT07171619",
      "title": "Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Nirogacestat",
          "type": "DRUG"
        },
        {
          "name": "Nirogacestat and Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Nirogacestat and Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2025-08-21",
      "completion_date": "2025-11-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-10-10T11:28:56.676Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07171619"
    },
    {
      "nct_id": "NCT05580770",
      "title": "Mirdametinib + BGB-3245 in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Mirdametinib 2mg",
          "type": "DRUG"
        },
        {
          "name": "BGB-3245 5mg",
          "type": "DRUG"
        },
        {
          "name": "Mirdametinib 3mg",
          "type": "DRUG"
        },
        {
          "name": "Mirdametinib 4mg",
          "type": "DRUG"
        },
        {
          "name": "BGB-3245 10mg",
          "type": "DRUG"
        },
        {
          "name": "BGB-3245 20mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2023-02-03",
      "completion_date": "2025-01-15",
      "has_results": true,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-10T11:28:56.676Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • New Haven, Connecticut • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05580770"
    },
    {
      "nct_id": "NCT05028166",
      "title": "Individual Patient Compassionate Use of Mirdametinib",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Neurofibromatosis Type 1-Associated Plexiform Neurofibromas",
        "Histiocytic Neoplasm",
        "Other MAP-K Pathway Driven Diseases"
      ],
      "interventions": [
        {
          "name": "Mirdametinib (MEK Inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-10T11:28:56.676Z",
      "location_count": 1,
      "location_summary": "Billerica, Massachusetts",
      "locations": [
        {
          "city": "Billerica",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05028166"
    },
    {
      "nct_id": "NCT05348356",
      "title": "Nirogacestat in Ovarian Granulosa Cell Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Granulosa-Stromal Tumor",
        "Ovarian Granulosa Cell Tumor",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Nirogacestat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 53,
      "start_date": "2022-08-30",
      "completion_date": "2025-07-14",
      "has_results": true,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-10T11:28:56.676Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Orlando, Florida • Tampa, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05348356"
    },
    {
      "nct_id": "NCT06997276",
      "title": "Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "Mirdametinib (MEK Inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 32,
      "start_date": "2025-05-07",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-10T11:28:56.676Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Orlando, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06997276"
    },
    {
      "nct_id": "NCT03962543",
      "title": "MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plexiform Neurofibroma",
        "Neurofibromatosis Type 1 (NF1)"
      ],
      "interventions": [
        {
          "name": "Mirdametinib (PD-0325901) oral capsule or dispersible tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2019-09-29",
      "completion_date": "2028-12-22",
      "has_results": true,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-10T11:28:56.676Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03962543"
    },
    {
      "nct_id": "NCT07279233",
      "title": "To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Volunteer"
      ],
      "interventions": [
        {
          "name": "Mirdametinib",
          "type": "DRUG"
        },
        {
          "name": "Mirdametinib and Carbamazepine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2025-12-15",
      "completion_date": "2026-02-27",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-10-10T11:28:56.676Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07279233"
    },
    {
      "nct_id": "NCT06251310",
      "title": "SW-682 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Mesothelioma, Malignant"
      ],
      "interventions": [
        {
          "name": "SW-682",
          "type": "DRUG"
        },
        {
          "name": "Combination Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2024-07-31",
      "completion_date": "2027-01-18",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-10T11:28:56.676Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06251310"
    }
  ]
}